<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Starpharma Holdings Ltd — News on 6ix</title>
<link>https://6ix.com/company/starpharma-holdings-ltd</link>
<description>Latest news and press releases for Starpharma Holdings Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:12 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/starpharma-holdings-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836698178dffbe2df15f241.webp</url>
<title>Starpharma Holdings Ltd</title>
<link>https://6ix.com/company/starpharma-holdings-ltd</link>
</image>
<item>
<title>FDA confirms path to DEP HER2 first-in-human study</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/fda-confirms-path-to-dep-her2-first-in-human-study</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/fda-confirms-path-to-dep-her2-first-in-human-study</guid>
<pubDate>Tue, 21 Apr 2026 04:00:12 GMT</pubDate>
<description>FDA confirms path to DEP HER2 first-in-human study</description>
</item>
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/half-yearly-report-and-accounts-224</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/half-yearly-report-and-accounts-224</guid>
<pubDate>Wed, 18 Feb 2026 02:58:20 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-49</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-49</guid>
<pubDate>Thu, 29 Jan 2026 04:21:05 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>AGM Chair address and CEO presentation</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/agm-chair-address-and-ceo-presentation-1</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/agm-chair-address-and-ceo-presentation-1</guid>
<pubDate>Fri, 14 Nov 2025 07:26:03 GMT</pubDate>
<description>AGM Chair address and CEO presentation</description>
</item>
<item>
<title>Upfront payment of USD $5.5 million received from Genentech</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/upfront-payment-of-usd-dollar55-million-received-from-genentech</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/upfront-payment-of-usd-dollar55-million-received-from-genentech</guid>
<pubDate>Wed, 22 Oct 2025 03:46:03 GMT</pubDate>
<description>Upfront payment of USD $5.5 million received from Genentech</description>
</item>
<item>
<title>SPL:Research & Option Agreement with Radiopharm Theranostics</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/splresearch-and-option-agreement-with-radiopharm-theranostics</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/splresearch-and-option-agreement-with-radiopharm-theranostics</guid>
<pubDate>Tue, 30 Sep 2025 04:06:05 GMT</pubDate>
<description>SPL:Research & Option Agreement with Radiopharm Theranostics</description>
</item>
<item>
<title>Starpharma Announces a Collaboration and License Agreement with Genentech</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-announces-collaboration-license-agreement-113000026</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-announces-collaboration-license-agreement-113000026</guid>
<pubDate>Mon, 22 Sep 2025 11:30:00 GMT</pubDate>
<description>MELBOURNE, Australia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, US OTC: SPHRY), an innovative Australian biotechnology company, today announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma’s proprietary DEP® drug delivery technology. Starpharma will receive an upfront payment of USD $5.5 million (~AUD $8.3 million), and is eligible for development, commercial, and ne</description>
</item>
<item>
<title>Presentation to Accompany License Agreement with Genentech</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/presentation-to-accompany-license-agreement-with-genentech</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/presentation-to-accompany-license-agreement-with-genentech</guid>
<pubDate>Mon, 22 Sep 2025 03:18:19 GMT</pubDate>
<description>Presentation to Accompany License Agreement with Genentech</description>
</item>
<item>
<title>Starpharma Announces License Agreement with Genentech</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-announces-license-agreement-with-genentech</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-announces-license-agreement-with-genentech</guid>
<pubDate>Mon, 22 Sep 2025 03:11:10 GMT</pubDate>
<description>Starpharma Announces License Agreement with Genentech</description>
</item>
<item>
<title>$3.7M R&D Tax Incentive Received</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/dollar37m-randd-tax-incentive-received</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/dollar37m-randd-tax-incentive-received</guid>
<pubDate>Thu, 28 Aug 2025 03:51:28 GMT</pubDate>
<description>$3.7M R&D Tax Incentive Received</description>
</item>
<item>
<title>FY25 Key Financial Results and Annual Report</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/fy25-key-financial-results-and-annual-report</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/fy25-key-financial-results-and-annual-report</guid>
<pubDate>Tue, 26 Aug 2025 05:16:04 GMT</pubDate>
<description>FY25 Key Financial Results and Annual Report</description>
</item>
<item>
<title>2025 Appendix 4E Preliminary Financial Report</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/2025-appendix-4e-preliminary-financial-report</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/2025-appendix-4e-preliminary-financial-report</guid>
<pubDate>Tue, 26 Aug 2025 05:02:14 GMT</pubDate>
<description>2025 Appendix 4E Preliminary Financial Report</description>
</item>
<item>
<title>SPL receives positive FDA feedback on DEP SN38 for PROC</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/spl-receives-positive-fda-feedback-on-dep-sn38-for-proc</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/spl-receives-positive-fda-feedback-on-dep-sn38-for-proc</guid>
<pubDate>Thu, 19 Dec 2024 04:02:17 GMT</pubDate>
<description>SPL receives positive FDA feedback on DEP SN38 for PROC</description>
</item>
<item>
<title>AGM Chair's address and CEO's presentation</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/agm-chairs-address-and-ceos-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/agm-chairs-address-and-ceos-presentation</guid>
<pubDate>Tue, 26 Nov 2024 07:43:12 GMT</pubDate>
<description>AGM Chair's address and CEO's presentation</description>
</item>
<item>
<title>SPL7013 Nasal Spray Australia Update</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/spl7013-nasal-spray-australia-update</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/spl7013-nasal-spray-australia-update</guid>
<pubDate>Fri, 18 Oct 2024 02:43:26 GMT</pubDate>
<description>SPL7013 Nasal Spray Australia Update</description>
</item>
<item>
<title>Starpharma Receives $5.5M R&D Tax Incentive Refund</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-receives-dollar55m-randd-tax-incentive-refund</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-receives-dollar55m-randd-tax-incentive-refund</guid>
<pubDate>Thu, 12 Sep 2024 03:51:04 GMT</pubDate>
<description>Starpharma Receives $5.5M R&D Tax Incentive Refund</description>
</item>
<item>
<title>Annual Report to shareholders</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/annual-report-to-shareholders-19</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/annual-report-to-shareholders-19</guid>
<pubDate>Thu, 22 Aug 2024 03:29:24 GMT</pubDate>
<description>Annual Report to shareholders</description>
</item>
<item>
<title>Positive final DEP irinotecan Phase 2 clinical trial results</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/positive-final-dep-irinotecan-phase-2-clinical-trial-results</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/positive-final-dep-irinotecan-phase-2-clinical-trial-results</guid>
<pubDate>Mon, 27 May 2024 04:36:05 GMT</pubDate>
<description>Positive final DEP irinotecan Phase 2 clinical trial results</description>
</item>
<item>
<title>Starpharma Business Update</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-business-update</guid>
<pubDate>Wed, 22 May 2024 04:47:21 GMT</pubDate>
<description>Starpharma Business Update</description>
</item>
<item>
<title>Starpharma and Medicxi Partnership Petalion Therapeutics</title>
<link>https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-and-medicxi-partnership-petalion-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/starpharma-holdings-ltd/news/starpharma-and-medicxi-partnership-petalion-therapeutics</guid>
<pubDate>Mon, 08 Apr 2024 03:46:07 GMT</pubDate>
<description>Starpharma and Medicxi Partnership Petalion Therapeutics</description>
</item>
</channel>
</rss>